Email This Content
Send an email to a colleague about this document. Non-subscribers may purchase the article.© Copyright 2010 WINDHOVER INFORMATION INC., All Rights Reserved
Windhover Information Inc. - Health Care Business Intelligence
Delivering essential analysis and insights to top health care executives, investment professionals, and industry consultants
By Christopher Morrison, IN VIVO 7/1/2007
IN VIVO -- Alnylam's monster deal with Roche for non-exclusive rights to the biotech's RNAi platform across four therapeutic areas sets the bar for technology platform monetization. Not only is Alnylam gaining $331 million in upfront payments, it can turn around and re-license those same rights at any time. Roche is for the first time making a splash in RNAi, which it and other companies are betting will be a new therapeutic modality.
For $85, purchase this 1282-word article as a PDF, and receive immediate delivery via email. View a complete sample article.
Questions? Call Toll Free (800) 332-2181 or (908) 547-2159.
100% Satisfaction Guarantee
If you are already a subscriber, please log in for complete access. 
Questions? Call Toll Free (800) 332-2181 or (908) 547-2159.
Click an article title to see a free preview.
New Channels to Biotech Exits? Not Anytime Soon, at Least., The IN VIVO Blog 7/1/2008
Best of the Blog: IN VIVO, June 2008, IN VIVO 6/1/2008
DotW: Easy Livin', The IN VIVO Blog 6/1/2008
Takeda's Global Ambition, IN VIVO 6/1/2008
Takeda's Millions Buy a Lot of Beer, The IN VIVO Blog 5/1/2008
Isis: Pondering Platform Power, IN VIVO 4/1/2008
Pharmaceutical Strategic Outlook: The Trouble with Alliances, IN VIVO 4/1/2008
Dispatch from BIO-Windhover: When Licensing Bleeds Value from Biotech, The IN VIVO Blog 3/1/2008
Back in Fashion: Discovery Platforms (Certain Kinds, at Least), IN VIVO 2/1/2008
